We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+29.15%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$4.65B
AUM Growth
+$951M
Cap. Flow
+$238M
Cap. Flow %
5.12%
Top 10 Hldgs %
42.35%
Holding
109
New
44
Increased
20
Reduced
16
Closed
29

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$233M
2
OTIS icon
Otis Worldwide
OTIS
+$135M
3
RPRX icon
Royalty Pharma
RPRX
+$107M
4
BAX icon
Baxter International
BAX
+$105M
5
FIVE icon
Five Below
FIVE
+$104M

Top Sells

Rank Stock Value
1
CRM icon
Salesforce
CRM
+$226M
2
BSX icon
Boston Scientific
BSX
+$147M
3
JNJ icon
Johnson & Johnson
JNJ
+$121M
4
FIS icon
Fidelity National Information Services
FIS
+$99.8M
5
AMZN icon
Amazon
AMZN
+$68.2M

Sector Composition

Rank Sector Weight
1 Healthcare 22.01%
2 Technology 20.81%
3 Industrials 20.34%
4 Consumer Discretionary 17.45%
5 Communication Services 11.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLQT icon
51
SelectQuote
SLQT
$121M
$13M 0.28%
+514,545
New +$13.8M
ADCT icon
52
ADC Therapeutics
ADCT
$144M
$8.2M 0.18%
+175,090
New +$6.65M
DKNG icon
53
DraftKings
DKNG
$11.9B
$7.05M 0.15%
+211,846
New +$5.86M
STRO icon
54
Sutro Biopharma
STRO
$421M
$7.01M 0.15%
90,280
+82,180
+1,015% +$7.89M
SLNO
55
DELISTED
Soleno Therapeutics
SLNO
$5.61M 0.12%
+168,492
New +$7.3M
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.08M 0.11%
+500,000
New +$4.6M
LEGN icon
57
Legend Biotech
LEGN
$4.01B
$4.26M 0.09%
+100,000
New +$3.91M
IMVT icon
58
Immunovant
IMVT
$8.25B
$4.09M 0.09%
167,884
+131,784
+365% +$2.82M
CHRS icon
59
Coherus Oncology
CHRS
$196M
$3.24M 0.07%
181,300
+100,000
+123% +$1.69M
GSAH.U
60
DELISTED
GS Acquisition Holdings Corp II Units, each consisting of one share of Class A Common Stock and one-
GSAH.U
$3.15M 0.07%
+300,000
New +$3.15M
SURF
61
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$3.13M 0.07%
+476,879
New +$1.72M
PLRX icon
62
Pliant Therapeutics
PLRX
$65M
$3.07M 0.07%
+94,700
New +$2.51M
KALV
63
DELISTED
KalVista Pharmaceuticals
KALV
$2.99M 0.06%
247,000
+132,800
+116% +$1.41M
KZR
64
DELISTED
Kezar Life Sciences
KZR
$2.88M 0.06%
55,590
+46,600
+518% +$2.35M
ADAP
65
DELISTED
Adaptimmune Therapeutics
ADAP
$2.69M 0.06%
+268,900
New +$1.69M
CCXI
66
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$2.59M 0.06%
+45,000
New +$2.45M
ORIC icon
67
Oric Pharmaceuticals
ORIC
$1.4B
$2.58M 0.06%
+76,432
New +$2.44M
FATE icon
68
Fate Therapeutics
FATE
$326M
$2.57M 0.06%
+75,000
New +$2.24M
CLOVW
69
DELISTED
Clover Health Investments, Corp. Warrants
CLOVW
$2.53M 0.05%
+844,196
New +$2.35M
AUPH icon
70
Aurinia Pharmaceuticals
AUPH
$2.11B
$2.53M 0.05%
155,700
+74,900
+93% +$1.2M
BLU
71
DELISTED
BELLUS Health Inc.
BLU
$2.48M 0.05%
+240,900
New +$2.44M
ALBO
72
DELISTED
Albireo Pharma Inc
ALBO
$2.14M 0.05%
80,900
+31,900
+65% +$752K
EIGR
73
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.91M 0.04%
6,647
+1,320
+25% +$389K
KDNY
74
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.85M 0.04%
+160,580
New +$2.21M
ARYBU
75
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$1.74M 0.04%
+150,000
New +$1.65M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Suvretta Capital Management held 109 positions worth $4.65B, up 26% from $3.7B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Suvretta Capital Management deployed $238M of net new capital in Q2 2020, opening 44 new positions and adding to 20 existing holdings. Its largest new stake was Meta Platforms (Facebook): 1,114,740 shares worth $253M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 26% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $147M trimmed.

  • Suvretta Capital Management's largest Q2 2020 buy was Meta Platforms (Facebook): 1,114,740 shares worth $253M.
  • Suvretta Capital Management added most to Uber in Q2 2020, an estimated $82.8M increase.
  • Suvretta Capital Management's biggest Q2 2020 reduction was Boston Scientific, cutting an estimated $147M.
  • Suvretta Capital Management fully exited Salesforce in Q2 2020, selling an estimated $226M.
  • Suvretta Capital Management's ten largest holdings make up 42% of its $4.65B portfolio in Q2 2020.
  • Suvretta Capital Management opened 44 new positions and closed 29 in Q2 2020.
  • Suvretta Capital Management's portfolio value rose 26% quarter-over-quarter to $4.65B.

Based on Suvretta Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.